Biogen Adds Pfizer’s PF-05251749 to its Neuroscience Pipeline in US$710 M Deal
By Neha Madhwani
Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)
Published: 4 Feb-2020
DOI: 10.3833/pdr.v2020.i2.2511 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Biogen has agreed to acquire Pfizer’s PF-05251749, a Phase I asset in development for the treatment of Alzheimer’s disease (AD) and Parkinson’s disease (PD), in exchange for US$75 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS